Sonoma Pharmaceuticals (NASDAQ:SNOA) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Sonoma Pharmaceuticals (NASDAQ:SNOA) posted its earnings results on Tuesday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06), Zacks reports. The company had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $5.47 million. Sonoma Pharmaceuticals had a negative net margin of 19.04% and a negative return on equity of 42.56%.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA stock opened at $2.75 on Friday. The firm’s 50-day moving average is $3.43 and its two-hundred day moving average is $3.76. Sonoma Pharmaceuticals has a 12 month low of $1.75 and a 12 month high of $6.92. The company has a market capitalization of $4.76 million, a PE ratio of -1.35 and a beta of 1.65.

Institutional Trading of Sonoma Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in SNOA. McKinley Carter Wealth Services Inc. purchased a new stake in Sonoma Pharmaceuticals during the fourth quarter worth about $41,000. Heron Bay Capital Management acquired a new position in shares of Sonoma Pharmaceuticals in the second quarter valued at approximately $96,000. Finally, DRW Securities LLC grew its holdings in shares of Sonoma Pharmaceuticals by 257.2% in the fourth quarter. DRW Securities LLC now owns 60,977 shares of the company’s stock valued at $222,000 after purchasing an additional 43,907 shares in the last quarter. Institutional investors and hedge funds own 1.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.